VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2021 | myDRUG: precision medicine in multiple myeloma

Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses precision medicine approaches for the treatment of patients with multiple myeloma. Dr AuClair describes the myDRUG trial (NCT03732703) which is investigating precision medicine approaches in patients with multiple myeloma by using genomic profiling and drugs targeted to affect specific disease-related mutations. Dr AuClair also describes a case study from the myDRUG trial where a mutation in the RAS pathway was identified in patient with myeloma, enabling targeted therapy with promising results. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter